Category Reports Biotech

The FDA’s second no on RP1 plus nivolumab in advanced melanoma does not look like a simple administrative delay. It is a rejection that hits the core regulatory thesis, reopens the debate around the program’s near-term value and forces a broader reassessment of the Replimune story as a strategic reset rather than a delayed approval thesis.

The key change since the December 2025 approval is simple: the stock is no longer being judged mainly on whether CARDAMYST can reach the market, but on whether Milestone can actually turn that approval into real access, real prescriptions, real repeat physician behavior, and eventually a broader etripamil franchise beyond PSVT. That sounds less dramatic than a PDUFA setup, but it is usually the more important phase. Approval can rerate a story for a week. Commercial traction is what can rerate it for much longer.

This update picks up the story where the earlier Merlintrader pieces left it: global expansion, label-expansion ambition and clinical momentum were still moving forward, but the market narrative suddenly shifted when the FDA’s Office of Prescription Drug Promotion publicly challenged how ANKTIVA had been promoted. The key question now is not whether the issue existed — it did — but whether the company’s remediation plan is enough to contain the damage while the underlying commercial story keeps improving.

This April update picks up the OCUL story where our earlier Merlintrader pieces left it: from the pre-readout run-up and takeover chatter, through the February SOL-1 topline and the violent sell-the-news reaction, to the next regulatory, scientific and commercial steps that now matter most.

ELAB is no longer just a tiny “obesity + AI + low float” story. Since the prior Merlintrader article, the company has added another manufacturing asset, widened the NorthStrive pipeline, opened a new defense-tech lane, and fully tapped a $20 million Streeterville facility. That gives it more operational breadth, but it also hardens the core problem: cash is less immediate, dilution is more real, and execution now has to work across biotech, industrial integration and defense optionality at the same time.

A full bilingual deep dive built around the real moving parts of the Lexicon story in April 2026: the Zynquista resubmission path after the 2024 complete response letter, the mid-2026 enrollment target for SONATA-HCM, the cash and dilution picture after the January-February 2026 financing, the economics of the Novo Nordisk LX9851 deal, and the structural risks that still make this name a high-volatility small-cap biotech setup.

Adagio Medical is a very small-cap, pre-commercial medtech name trying to carve out a meaningful niche in ventricular tachycardia ablation with its proprietary ultra-low temperature cryoablation platform. What makes the story relevant now is not revenue momentum, because there really is not much of that yet, but the combination of a pivotal study that has already completed enrollment, encouraging acute data, and a fresh FDA IDE expansion that lets the company clinically evaluate its next-generation ventricular catheter while the broader regulatory path remains open.

After three Complete Response Letters and a long fight over what counts as sufficient evidence for ONS-5010 / LYTENAVA in wet AMD, Outlook Therapeutics has now moved into a formal FDA dispute-resolution process. This article walks through the CRL history, the new April 2026 meeting, and the real powers of the FDA deciding official — without hype, but also without pretending the door is already shut.

Why this follow-up exists
REVEAL-1 did not kill the TED thesis, but it changed the bar. The debate has moved from “does the drug work?” to “can Viridian still build a differentiated TED franchise that deserves premium valuation?”